Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates 🔗 Access full article via Cell ImmunityShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
